Ticker LaunchFiled, not priced · TARX
Tarsier Pharma Ltd.
Tarsier Pharma Ltd. publicly filed a registration statement on Form F-1 on Apr 21, 2026 for a proposed initial public offering on NYSE under the ticker TARX, and has not yet priced. Its latest amendment was filed on Jul 16, 2026. Underwriters named in the filing: Konik Capital Partners and T.R. Winston.
Tarsier Pharma Ltd. is a late clinical-stage biopharmaceutical company developing therapies for blinding inflammatory eye diseases. Its dazdotuftide platform immunomodulator is being developed as eye drops (TRS01) and intravitreal injections (TRS02).
- Status
- Filed, not priced
- Ticker
- TARX
- Exchange
- NYSE
- First filed
- Apr 21, 2026
- Latest amendment
- Jul 16, 2026
- Underwriters
- Konik Capital Partners and T.R. Winston
- Sector
- Biotech & pharma
More on this listing for subscribers
- Amendment history
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (F-1) first filed Apr 21, 2026
- Latest amendment Jul 16, 2026
- All filings on EDGAR CIK 2102720
Other companies in the IPO pipeline
- Ambitious Entertainment, Inc.May 15, 2026
- Web3Labs Global Inc.May 13, 2026
- Suchness Tech LtdMay 12, 2026
- MetaOptics LtdMay 4, 2026
- ROKIT America, Inc.Apr 15, 2026
- Encore Inc.Apr 10, 2026